NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement.
Personalized medicine in oncology is maturing and evolving rapidly, and the use of molecular biomarkers in clinical decision-making is growing. This raises important issues regarding the safe, effective, and efficient deployment of molecular tests to guide appropriate care, specifically regarding laboratory-developed tests and companion diagnostics. In May 2011, NCCN assembled a work group composed of thought leaders from NCCN Member Institutions and other organizations to identify challenges and provide guidance regarding molecular testing in oncology and its corresponding utility from clinical, scientific, and coverage policy standpoints. The NCCN Molecular Testing Work Group identified challenges surrounding molecular testing, including health care provider knowledge, determining clinical utility, coding and billing for molecular tests, maintaining clinical and analytic validity of molecular tests, efficient use of specimens, and building clinical evidence.
Paul F
PF
Engstrom
Mara G
MG
Bloom
George Daniel
GD
Demetri
Phillip G
PG
Febbo
William
W
Goeckeler
Marc
M
Ladanyi
Bryan
B
Loy
Kate
K
Murphy
Michael
M
Nerenberg
Paul
P
Papagni
Mark
M
Robson
Robert W
RW
Sweetman
Sean
S
Tunis
Jessica
J
Demartino
Jonathan K
JK
Larsen
D014408:Biomarkers, Tumor / Q000032:analysis; D006801:Humans; D008495:Medical Oncology / Q000379:methods / Q000592:standards* / Q000639:trends; D008967:Molecular Biology / Q000379:methods* / Q000592:standards* / Q000639:trends; D009369:Neoplasms / Q000175:diagnosis* / Q000235:genetics*
D014408:Biomarkers, Tumor